Autopsy report · NCT01072591

Study to Assess MEDI -578 in Patients With Osteoarthritis (OA) of the Knee

“Amended clinical development plan.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 7 months before it stopped.
• 108 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

AstraZeneca

Sponsor type

Industry

Conditions

Osteoarthritis; Pain

Interventions

MEDI-578; Placebo for MEDI-578

Participants

108

Sites

1

Countries

United Kingdom

Trials that died the same way

• Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients
  “Change in the clinical development plan” (88% match in meaning)
• Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
  “the change of clinical development plan” (87% match in meaning)
• Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for ARDS
  “Change in development plan” (70% match in meaning)
• A Safety and Efficacy Study Evaluating ET-01 in Subjects with Transfusion Dependent Β-Thalassaemia
  “Development plan change” (69% match in meaning)
• A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors
  “The sponsor adjusts the clinical development strategy.” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.